Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma

B. Szende, A. Horváth, G. Bökönyi, G. Kéri

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg-1 being the most effective. Combination of 1 mg kg-1 TT-232 with 30 or 60 mg kg-1 DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle - lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg-1 TT-232 or 60 mg kg-1, but not of 30 mg kg-1 DTIC. TT-232, combined with 30 or 60 mg Kg-1 DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg-1 TT-232. 5 mg kg-1 etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg-1 TT-232 and 5 mg kg-1 etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg-1 etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma.

Original languageEnglish
Pages (from-to)132-136
Number of pages5
JournalBritish Journal of Cancer
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 13 2003

Fingerprint

Experimental Melanomas
Somatostatin
Heterografts
Dacarbazine
Neoplasm Metastasis
Pharmaceutical Preparations
Etoposide
Neoplasms
Melanoma
Lymphoma
Lung
TT2-32
Growth
Therapeutics
Combination Drug Therapy
Cell Culture Techniques

Keywords

  • Dacarbazine
  • Etoposide
  • Lymphoma
  • Melanoma
  • Somatostatin
  • TT-232

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. / Szende, B.; Horváth, A.; Bökönyi, G.; Kéri, G.

In: British Journal of Cancer, Vol. 88, No. 1, 13.01.2003, p. 132-136.

Research output: Contribution to journalArticle

@article{1e068808affa4ab9ae23780c1bd5f13e,
title = "Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma",
abstract = "A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg-1 being the most effective. Combination of 1 mg kg-1 TT-232 with 30 or 60 mg kg-1 DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle - lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg-1 TT-232 or 60 mg kg-1, but not of 30 mg kg-1 DTIC. TT-232, combined with 30 or 60 mg Kg-1 DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50{\%} growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg-1 TT-232. 5 mg kg-1 etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg-1 TT-232 and 5 mg kg-1 etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg-1 etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma.",
keywords = "Dacarbazine, Etoposide, Lymphoma, Melanoma, Somatostatin, TT-232",
author = "B. Szende and A. Horv{\'a}th and G. B{\"o}k{\"o}nyi and G. K{\'e}ri",
year = "2003",
month = "1",
day = "13",
doi = "10.1038/sj.bjc.6600668",
language = "English",
volume = "88",
pages = "132--136",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma

AU - Szende, B.

AU - Horváth, A.

AU - Bökönyi, G.

AU - Kéri, G.

PY - 2003/1/13

Y1 - 2003/1/13

N2 - A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg-1 being the most effective. Combination of 1 mg kg-1 TT-232 with 30 or 60 mg kg-1 DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle - lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg-1 TT-232 or 60 mg kg-1, but not of 30 mg kg-1 DTIC. TT-232, combined with 30 or 60 mg Kg-1 DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg-1 TT-232. 5 mg kg-1 etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg-1 TT-232 and 5 mg kg-1 etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg-1 etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma.

AB - A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg-1 being the most effective. Combination of 1 mg kg-1 TT-232 with 30 or 60 mg kg-1 DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle - lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg-1 TT-232 or 60 mg kg-1, but not of 30 mg kg-1 DTIC. TT-232, combined with 30 or 60 mg Kg-1 DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg-1 TT-232. 5 mg kg-1 etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg-1 TT-232 and 5 mg kg-1 etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg-1 etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma.

KW - Dacarbazine

KW - Etoposide

KW - Lymphoma

KW - Melanoma

KW - Somatostatin

KW - TT-232

UR - http://www.scopus.com/inward/record.url?scp=0037434429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037434429&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600668

DO - 10.1038/sj.bjc.6600668

M3 - Article

C2 - 12556972

AN - SCOPUS:0037434429

VL - 88

SP - 132

EP - 136

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -